Status:

COMPLETED

Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics

Lead Sponsor:

National Human Genome Research Institute (NHGRI)

Conditions:

Data Analysis

Cancer Genetics

Eligibility:

All Genders

Brief Summary

The researchers have developed and distributed several software packages for pedigree analysis (FAST, CASPAR, PedHunter, IIC) and cancer genetics (oncotree, METREX). Users who need assistance with the...

Detailed Description

We have developed software packages for pedigree analysis (FAST, CASPAR, PedHunter, IIC) and cancer genetics (oncotrees, METREX). The purpose of this protocol is to allow us to work on software proble...

Eligibility Criteria

Inclusion

  • INCLUSION/EXCLUSION CRITERIA:
  • User Requests:
  • When receiving data sets for problem reports and/or new feature requests, all data sets would be accepted. We would not consider how the data were collected. The reasons for this are: the medical aspects of the data set are irrelevant to the reason we receiving the data; we cannot respond promptly to problem reports, if we have to get details on how the data were collected; the data are never used by us for any research into the traits being studies by the researchers who collected data.
  • Collaborations:
  • For collaborative studies, we would request details of how the data were collected, including evidence of approval by a local ethics board. We would submit to the NHGRI IRB an amendment describing the new collaboration. That amendment would necessarily include a formal indication that the collaborating research group has permission to collect and analyze the human data that they present to us (in coded and summarized format). For collaborators in the United States that permission would consist of an IRB-approved protocol or exemption from the collaborator's institution. For collaborators outside the United States the permission would be one of the types of agreements currently supported by the NIH Office of Human Subjects Research.
  • If we do not see evidence of appropriate permission to collect the data or the IRB turns down our proposed amendment, then we would exclude ourselves from participating in the proposed collaboration.
  • There are two other circumstances under which we have also excluded collaborating on analysis of data sets in the past and may do so in the future. One circumstance was where we did not feel that the proposed data set could possibly give sufficient statistical power to detect anything interesting. The other circumstance was where we had an existing collaboration with one research group, and a competing group asked us to collaborate also.

Exclusion

    Key Trial Info

    Start Date :

    March 19 2002

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    May 9 2017

    Estimated Enrollment :

    13385 Patients enrolled

    Trial Details

    Trial ID

    NCT00339508

    Start Date

    March 19 2002

    End Date

    May 9 2017

    Last Update

    April 5 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Human Genome Research Institute (NHGRI), 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892